ClinicalTrials.gg
Status unknownNCT05790941Updated Mar 30, 2023

Proof of Concept Study of Latanoprost/Minoxidil (ANR-001.1) Topical Formulation

An Early Phase 1 interventional study of Latanoprost and Minoxidil in Hypotrichosis, sponsored by Aneira Pharma, Inc.. Status unknown at 1 site in United States. Open to participants aged 22 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-03-30.

Sponsored by Aneira Pharma, Inc. · Early Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Feb 2023), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
22 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Hypotrichosis with a site in United States — 2 open to participants now, 3 under way, 1 of them phase 3. Hypotrichosis · United States.

Planned enrollment
13th of 14
12 · median 89
Started
2023
with 1 other
Phase 1
Only one
of the 15
Registered
14th of 15
by date
Lead sponsor
1 of 15
Aneira Pharma, Inc.

Among the 15 studies in Hypotrichosis with a site in United States, this one is the 13th largest by planned enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2023, is the only one in phase 1, and was the 14th registered.

Hypotrichosis

24 studies on the registry are indexed under Hypotrichosis; 2 are open to participants now.

Browse Hypotrichosis studies →

Open to participants now

2 of the 15 studies in Hypotrichosis with a site in United States are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 2 Hypotrichosis studies recruiting now, none set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.

This study: 22 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Hypotrichosis with a site in United States, or all of them as a file.
02

Study summary

Study to Evaluate the safety and efficacy of a Latanoprost/Minoxidil formulation vs. placebo for the treatment of hypotrichosis of the eyebrows.

Read the detailed description

A Single-Blind placebo controlled trial of the efficacy and safety of the treatment of hypotrichosis of the eyebrows comparing a subset of patients receiving a combination of latanoprost/minoxidil formulation as compared to placebo measured by a validated imaging system.

03

Conditions studied

  • Hypotrichosis

Browse trials for

Keywords

  • Eyebrow
04

Who can participate

Ages eligible
22 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria: • Subjects, age 22 to 65 years, in general good health.

  • Patients with diagnosed hypotrichosis of the eyebrows.
  • Subjects with active hair loss within the last 12 months.
  • Patients willing to refrain from initiation of any new vitamins or nutritional supplements for the duration of the study.
  • Patients willing to refrain from use of any hair growth therapies (oral or topical) other than the product.

Exclusion Criteria: • Subjects with an active disease or infection, or chronic dermatological condition (eczema, psoriasis, infection, etc.) of the scalp that may interfere with the assessment of scalp skin health in the treated regions.

  • History of hair transplants, scalp reduction, current hair weave or tattooing in the target area, artificial hair coloring two months prior to initiation of study which makes it difficult to perform hair count assessment.
  • Subjects with hair loss for greater than 5 years, as medical therapy is unlikely to have much effect at restoring hair follicles inactive for that long of a time period.
  • Subjects with a history of chemotherapy, receiving cytotoxic agents, radiation, or laser/surgical therapy of the scalp within the past 12 months.
  • Any known or underlying medical problem that could influence hair growth such as infection, connective tissue disease, a thyroid condition, inflammatory bowel disease or other medical conditions, at the discretion of the investigator.
  • Subjects with clinical diagnosis of hair loss other than hypotrichosis of the eyebrows.
  • Subjects with severe cardiovascular disease, uncontrolled or untreated hypertension, arrythmia or hypotension.
  • Subjects with known or suspected or allergic reaction to any of the active or inactive components of the test articles.
  • Pregnant or lactating females or planning to become pregnant for the duration of the study.
  • Subjects using medications that potentially cause drug-induced hair loss (e.g., depotestosterone, haloperidol, methotrexate, methylprednisolone, prednisone, testosterone, divalproex sodium) within the last 3 months.
  • Current enrollment in any other investigational medication (drug) study within the 4 weeks prior to study initiation.
  • Current or recent (2 months) history of severe diet or eating disorder.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Single (Participant)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    Topical Latanoprost/Minoxidil formulation

    8 participants: Topical Latanoprost/Minoxidil formulation applied to both eyebrows once a day for 90 days

    Combination Product: Latanoprost and Minoxidil

  • Placebo comparator
    Control Group

    4 participants: Vehicle applied to both eyebrows once a day for 90 days

    Combination Product: Latanoprost and Minoxidil

Interventions

  • Combination productLatanoprost and Minoxidil

    Drug pages: Latanoprost · Minoxidil

    Latanoprost and Minoxidil formulation for the treatment of hypotrichosis of the eyebrows.

06

What researchers measure

Primary outcomes

  1. Target Area Hair Count

    Target Area Hair Count as Determined by the Brigham Tool for Alopecia

    Time frame: 90 days

Secondary outcomes

  1. Standardized Global Photographs

    1. Standardized Global Photographs and change from baseline measurement of eyebrow hair fullness using Canfield Eyebrow Hair Image Analysis.

    Time frame: 90 days

  2. Change in Total Area Hair Darkness

    2. Change in Total Area Hair Darkness of non-vellus hairs as compared to baseline in target area, defined as change from baseline of non-vellus hairs measured in intensity units as determined by Canfield Eyebrow Hair Image Analysis.

    Time frame: 90 days

Other outcomes

  1. Subject Self Assessment

    1. Subject Self-Assessment and Investigator Global Assessment using a Canfield side-by-side comparison tool on Day 90. Measure participant's satisfaction with eyebrow treatment.

    Time frame: 90 Days

07

Study locations

1 of 1 sites recruiting
  • WellMax
    Indian Wells, California 92210, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2023 (actual). Primary completion is estimated for Jun 2023, 3 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2023
First posted
Mar 30, 2023
StartActual
Mar 11, 2023
Primary completionEst.
Jun 30, 2023
CompletionEst.
Jun 30, 2023
Last update
Mar 30, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05790941
Lead sponsor
Aneira Pharma, Inc.
Responsible party
Sponsor
First posted
Mar 30, 2023
Start date
Mar 11, 2023
Primary completion
Jun 30, 2023 (estimated)
Completion
Jun 30, 2023 (estimated)
Last update
Mar 30, 2023

Study contacts

Dan Cosgrove, M.D.
Contact
heidi@wellmax.com
760-777-7698
Dan Cosgrove, M.D.
principal investigator · WellMax

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Latanoprost · Minoxidil

Start the discussion